Guardant Health, Inc.
GH
Classificação em ações
#1077
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Preço da ação
$162.03
Última sincronização: 2026-10-20
Valor de mercado
$21.74B
Variação (1 dia)
2.63%
Variação (1 ano)
140.01%
País
US
Negociar Guardant Health, Inc. (GH)
Categoria
Healthcare
Receita da Guardant Health, Inc. (GH)
Receita em Jun 2026 TTM: $1.18B
De acordo com os últimos relatórios financeiros da Guardant Health, Inc., a receita atual da empresa (TTM) é $1.18B. Em 2023, a empresa obteve uma receita de $563.95M um aumento em relação a a receita do ano 2022, que foi de $449.54M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Guardant Health, Inc. de 2016 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $1.18B | 60.09% |
| 2024 | $739.02M | 31.04% |
| 2023 | $563.95M | 25.45% |
| 2022 | $449.54M | 20.31% |
| 2021 | $373.65M | 30.32% |
| 2020 | $286.73M | 33.75% |
| 2019 | $214.38M | 136.52% |
| 2018 | $90.64M | 81.85% |
| 2017 | $49.84M | 97.40% |
| 2016 | $25.25M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $46.34B | 3,816.47% |
US
|
|
| $25.11B | 2,022.13% |
US
|
|
| $2.71B | 128.81% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 523.11% |
US
|
